NYSE:BAXBaxter International Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Baxter International Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $84.83 +2.32 (+2.81 %) (As of 04/8/2020 03:22 PM ET) Add Compare Share Today's Range$82.16Now: $84.83▼$84.9150-Day Range$71.57MA: $83.23▼$93.1652-Week Range$69.10Now: $84.83▼$95.00Volume188,608 shsAverage Volume3.32 million shsMarket Capitalization$43.03 billionP/E Ratio25.63Dividend Yield1.04%Beta0.88 ProfileAnalyst RatingsAdvanced ChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. It also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and by patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.Read More Beat the Market (BTM) Rank™ 2.3 Analyst's Opinion Consensus RatingBaxter International has received a consensus rating of Buy. The company's average rating score is 2.68, and is based on 13 buy ratings, 6 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $92.89, Baxter International has a potential upside of 9.9% from its current price of $84.52.Amount of Analyst CoverageBaxter International has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.7 Community Rank Outperform VotesBaxter International has received 671 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBaxter International has received 589 “underperform” votes. (Add your “underperform” vote.)Community SentimentBaxter International has received 53.25% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Baxter International and other stocks. Vote “Outperform” if you believe BAX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BAX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 3.3 Dividend Strength Dividend LeadershipBaxter International is a leading dividend payer. It pays a dividend yield of 1.04%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthBaxter International has only been increasing its dividend for 3 years.Dividend CoverageThe dividend payout ratio of Baxter International is 26.59 %. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Baxter International will have a dividend payout ratio of 22.00 % next year. This indicates that Baxter International will be able to sustain or increase its dividend. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Baxter International insiders have bought 133.64% more of their company's stock than they have sold. Specifically, they have bought $803,818.00 in company stock and sold $344,045.00 in company stock.Percentage Held by InsidersOnly 0.13% of the stock of Baxter International is held by insiders.Percentage Held by Institutions83.10% of the stock of Baxter International is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Baxter International are expected to grow by 12.36% in the coming year, from $3.56 to $4.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Baxter International is 25.53, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 12.21.Price to Earnings Ratio vs. SectorThe P/E ratio of Baxter International is 25.53, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 20.80.Price to Earnings Growth RatioBaxter International has a PEG Ratio of 1.95. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioBaxter International has a P/B Ratio of 5.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.3Community Rank: 2.7Dividend Strength: 3.3Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.60 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSE Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNYSE:BAX Previous Symbol CUSIP07181310 CIK10456 Webhttp://www.baxter.com/ Phone224-948-2000Debt Debt-to-Equity Ratio0.67 Current Ratio2.32 Quick Ratio1.81Price-To-Earnings Trailing P/E Ratio25.63 Forward P/E Ratio23.83 P/E Growth1.95 Sales & Book Value Annual Sales$11.36 billion Price / Sales3.79 Cash Flow$5.18 per share Price / Cash Flow16.39 Book Value$15.50 per share Price / Book5.47Profitability EPS (Most Recent Fiscal Year)$3.31 Net Income$1.00 billion Net Margins9.12% Return on Equity22.41% Return on Assets10.02%Miscellaneous Employees50,000 Outstanding Shares507,264,000Market Cap$43.03 billion Next Earnings Date4/23/2020 (Estimated) OptionableOptionable Receive BAX News and Ratings via Email Sign-up to receive the latest news and ratings for BAX and its competitors with MarketBeat's FREE daily newsletter. BAX Rates by TradingView Baxter International (NYSE:BAX) Frequently Asked Questions How has Baxter International's stock been impacted by COVID-19 (Coronavirus)? Baxter International's stock was trading at $77.97 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BAX stock has increased by 8.4% and is now trading at $84.52. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Baxter International? 19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Baxter International in the last year. There are currently 6 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Baxter International. When is Baxter International's next earnings date? Baxter International is scheduled to release its next quarterly earnings announcement on Thursday, April 23rd 2020. View our earnings forecast for Baxter International. How were Baxter International's earnings last quarter? Baxter International Inc (NYSE:BAX) announced its earnings results on Tuesday, March, 17th. The medical instruments supplier reported $0.97 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.88 by $0.09. The medical instruments supplier earned $2.85 billion during the quarter, compared to the consensus estimate of $2.87 billion. Baxter International had a return on equity of 22.41% and a net margin of 9.12%. The firm's revenue was up .4% on a year-over-year basis. During the same quarter last year, the business posted $0.80 earnings per share. View Baxter International's earnings history. How often does Baxter International pay dividends? What is the dividend yield for Baxter International? Baxter International declared a quarterly dividend on Tuesday, February 18th. Investors of record on Friday, February 28th will be paid a dividend of $0.22 per share on Wednesday, April 1st. This represents a $0.88 annualized dividend and a yield of 1.04%. The ex-dividend date is Thursday, February 27th. View Baxter International's dividend history. How will Baxter International's stock buyback program work? Baxter International announced that its board has approved a stock buyback plan on Tuesday, November 13th 2018, which permits the company to buyback $2,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to repurchase up to 6.1% of its stock through open market purchases. Stock buyback plans are typically an indication that the company's board believes its stock is undervalued. What guidance has Baxter International issued on next quarter's earnings? Baxter International updated its first quarter earnings guidance on Tuesday, March, 17th. The company provided earnings per share guidance of $0.72-0.74 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.81. What price target have analysts set for BAX? 19 Wall Street analysts have issued twelve-month target prices for Baxter International's stock. Their forecasts range from $75.00 to $104.00. On average, they anticipate Baxter International's share price to reach $92.89 in the next twelve months. This suggests a possible upside of 9.9% from the stock's current price. View analysts' price targets for Baxter International. Has Baxter International been receiving favorable news coverage? News stories about BAX stock have trended very negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Baxter International earned a news impact score of -3.3 on InfoTrie's scale. They also gave news stories about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutBaxter International. Are investors shorting Baxter International? Baxter International saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 6,344,100 shares, an increase of 27.9% from the February 27th total of 4,960,000 shares. Based on an average daily volume of 2,620,000 shares, the days-to-cover ratio is presently 2.4 days. Approximately 1.3% of the shares of the stock are sold short. View Baxter International's Current Options Chain. Who are some of Baxter International's key competitors? Some companies that are related to Baxter International include Abbott Laboratories (ABT), Medtronic (MDT), Becton Dickinson and (BDX), Stryker (SYK), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Insulet (PODD), Masimo (MASI) and Varian Medical Systems (VAR). What other stocks do shareholders of Baxter International own? Based on aggregate information from My MarketBeat watchlists, some companies that other Baxter International investors own include CA (CA), Honeywell International (HON), Johnson & Johnson (JNJ), Cisco Systems (CSCO), AT&T (T), BlackRock (BLK), Pfizer (PFE), Verizon Communications (VZ), Alibaba Group (BABA) and Home Depot (HD). Who are Baxter International's key executives? Baxter International's management team includes the following people: Mr. José E. Almeida, Chairman, Pres & CEO (Age 57)Mr. James K. Saccaro, Exec. VP & CFO (Age 46)Mr. Sean Martin, Sr. VP & Gen. Counsel (Age 56)Mr. Giuseppe Accogli, Sr. VP & Pres of Americas (Age 48)Mr. Scott Pleau, Sr. VP of Operations (Age 53) What is Baxter International's stock symbol? Baxter International trades on the New York Stock Exchange (NYSE) under the ticker symbol "BAX." Who are Baxter International's major shareholders? Baxter International's stock is owned by a number of retail and institutional investors. Top institutional shareholders include State of Alaska Department of Revenue (0.03%), Pensionfund DSM Netherlands (0.01%), Neville Rodie & Shaw Inc. (0.01%), Independent Investors Inc. (0.01%), Stillwater Investment Management LLC (0.00%) and M&R Capital Management Inc. (0.00%). Company insiders that own Baxter International stock include Albert P L Stroucken, Andrew Frye, Brik V Eyre, Carole J Shapazian, Giuseppe Accogli, Jacqueline Kunzler, James R Gavin III, Jeanne K Mason, John D Forsyth, Peter S Hellman, Scott Pleau, Sean Martin, Third Point Llc and Thomas T Stallkamp. View institutional ownership trends for Baxter International. Which institutional investors are selling Baxter International stock? BAX stock was sold by a variety of institutional investors in the last quarter, including Pensionfund DSM Netherlands, Stillwater Investment Management LLC, Fulton Bank N.A., Independent Investors Inc., M&R Capital Management Inc., and Neville Rodie & Shaw Inc.. Company insiders that have sold Baxter International company stock in the last year include Albert P L Stroucken, Andrew Frye, Jacqueline Kunzler, James R Gavin III, John D Forsyth, Third Point Llc, and Thomas T Stallkamp. View insider buying and selling activity for Baxter International. Which institutional investors are buying Baxter International stock? BAX stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, IBM Retirement Fund, Mitchell Sinkler & Starr PA, and Radnor Capital Management LLC. View insider buying and selling activity for Baxter International. How do I buy shares of Baxter International? Shares of BAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Baxter International's stock price today? One share of BAX stock can currently be purchased for approximately $84.52. How big of a company is Baxter International? Baxter International has a market capitalization of $42.87 billion and generates $11.36 billion in revenue each year. The medical instruments supplier earns $1.00 billion in net income (profit) each year or $3.31 on an earnings per share basis. Baxter International employs 50,000 workers across the globe. View additional information about Baxter International. What is Baxter International's official website? The official website for Baxter International is http://www.baxter.com/. How can I contact Baxter International? Baxter International's mailing address is One Baxter Parkway, Deerfield IL, 60015. The medical instruments supplier can be reached via phone at 224-948-2000 or via email at [email protected] This page was last updated on 4/8/2020 by MarketBeat.com StaffFeatured Article: What is the S&P 500 Index?
